StonvexLoading…
StonvexStonvexStonvexCore line items from FCX's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
| Metric | Q3 2026 (Est.) Expected 2026-07-21 | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|---|
Revenue | $6.62B | $6.25B | $25.19B | $19.92B | $13.10B |
Operating Income | Not available | $2.14B | $6.52B | $5.71B | $3.73B |
Net Income | Not available | $1.39B | $4.15B | $3.59B | $2.34B |
EPS (Diluted) | $0.54 | $0.61 | $1.52 | $1.24 | $0.77 |
Total Assets | Not available | $58.84B | $58.17B | $56.83B | $56.49B |
Total Liabilities | Not available | $27.33B | $27.40B | $26.43B | $26.50B |
Cash & Equivalents | Not available | $3.74B | $3.82B | $4.32B | $4.49B |
Free Cash Flow OCF − CapEx | Not available | $522.00M | $1.12B | $1.43B | $820.00M |
Shares Outstanding | Not available | 1.44B | 1.44B | 1.44B | 1.44B |